1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsADVOCATE (Agentic AI-Enabled Cardiovascular Care Transformation) Program is sponsored by Advanced Research Projects Agency for Health (ARPA-H). This program aims to develop the first FDA-authorized, agentic artificial intelligence (AI) technology that can provide 24/7 specialty care for cardiovascular disease.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Agentic AI-Enabled Cardiovascular Care Transformation What if an FDA-authorized clinical agentic AI could provide safe and effective cardiovascular care to every American?
Over 200,000 Americans die each year from preventable impacts of cardiovascular disease (CVD), the leading cause of death in the U.S. Despite spending almost half a trillion dollars on heart disease alone, the US experiences much worse outcomes than many other similar nations. Treatments for managing heart health with diet, exercise, and affordable medications are simple, inexpensive, and effective.
Yet nearly half of American counties lack a cardiologist, meaning that many patients across the country are missing out on life-saving care and interventions. Clinical artificial intelligence (AI) agents could help fill this gap, but we don’t currently have a clear way to ensure they consistently operate safely and effectively at scale in real-world settings.
The Agentic AI-EnableD CardioVascular CAre TransfOrmation (ADVOCATE) program aims to transform advanced cardiovascular disease management with an agentic AI system that can provide 24/7 holistic clinical care. ADVOCATE will support the development of clinical AI agents that can be trusted to autonomously adjust changes in appointments, medications, diet, and exercise.
In parallel, ADVOCATE will support the development of a supervisory AI "overseer” to monitor clinical AI agents after they have been deployed in clinical practice to ensure their continued safety and efficacy. ADVOCATE's transformative goal is to create a first-of-its-kind, reliable, FDA-authorized clinical agentic AI system that serves around the clock as a new, digital member of the clinical care team.
Together, these efforts will enable an integrated, holistic cardiovascular care platform to provide real-time guidance that patients and care teams can act on. The program will partner with health systems to successfully deploy the technology across diverse care environments—from major health systems to rural clinics and community settings.
Harness the power of American innovation to quickly develop agentic AI that is safe, transparent, and effective in healthcare settings. Unleash the best technical experts across sectors to tackle a leading cause of death in the U.S. and accelerate pathways for regulatory and reimbursement approvals.
Build trust with patients, doctors, and other stakeholders around patient-facing AI agents through rigorous testing and demonstrating measurable improvements in safety, outcomes, and equity. Pave the way for AI technology to serve as a clinician-extender, first for advanced CVD and eventually for all chronic conditions.
What ARPA-H needs to solve this problem ADVOCATE seeks leaders in the tech sector, academia, non-profit organizations, and small businesses to overcome the technical, regulatory, and market barriers holding back innovation in clinical agentic AI.
The program has three technical areas: development of a patient-facing clinical AI agent, a supervisory agent that ensures clinical AI agents’ consistent safety and effectiveness, and a scalable plan for integration into clinical workflows in healthcare organizations. Notice ID: ARPA-H-SOL-26-142 ARPA-H invites interested parties to review the solicitation, which is posted and maintained on SAM.
gov. The solicitation outlines the opportunity and its requirements, key dates and deadlines, submission documents and templates, evaluation criteria for submissions, and information on how to apply. Solution Summary Due: February 27, 2026 A summary is required to submit a full proposal.
Full Proposal Due: April 1, 2026 at 5:00PM ET After submission of a solution summary, proposers will either be encouraged or discouraged from submission of a full proposal. It is strongly recommended that only proposers who are encouraged to submit a full proposal do so. Reminder: Dates are estimates and subject to change.
Please reference the solicitation for the most up-to-date information as late submissions will not be reviewed. Review Solicitation Details Ready to apply? To submit a Solution Summary, sign-in to the ARPA-H Solutions site .
Please note: Because of significant interest in the ADVOCATE program—a signal of both the urgency of cardiovascular disease and the promise of clinical agentic AI—ADVOCATE is piloting secure large language model (LLM) tools to assist with the initial review of Solution Summaries. Read the full statement to learn more .
Frequently Asked Questions Review responses to common questions about this funding opportunity asked by others in the proposer community. You can also ask a question. Review FAQs and Ask A Question This is an optional event for the proposer community to learn more about this opportunity, ask questions, and make connections.
This event is not intended for patients, patient advocates, the media, or general interest audiences. View the Proposers' Day recording View the Lightning Talk presentations This optional webinar for the proposer community was an additional chance to ask questions and get clarification on the ADVOCATE ISO. See the Special Notice ( ARPA-H-SN-26-148 ) for additional details.
ARPA-H anticipates that teaming will be necessary to achieve the goals of ADVOCATE. Prospective proposers are encouraged to form teams with varied technical expertise to submit a research proposal. To facilitate this process, we have created a teaming page where prospective proposers can share their profiles and learn more about other interested parties.
"What we are trying to achieve with ADVOCATE is a technology that can essentially serve as a clinician-extender: an autonomous agent smart enough to understand patients’ treatment needs, which can both provide certain care autonomously as well as engage the clinical team as needed." ARPA-H to revolutionize cardiovascular disease management with clinical agentic AI
According to the current listing, eligibility includes: ARPA-H encourages teaming among leaders in technology, academia, and nonprofit organizations. Confirm the full requirements in the official notice before applying.
ADVOCATE (Agentic AI-Enabled Cardiovascular Care Transformation) Program is funded by Advanced Research Projects Agency for Health (ARPA-H). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The Emerging Health Innovators solicitation drops on SAM.gov by the end of September 2026 with 16 named topic areas, an eight-year terminal-degree ceiling, and an eligibility screen that bars national labs, FFRDCs, UARCs, and anyone who has ever led an ARPA prime award. Proposers' Day is October 13. Here is how to read the design.
Read articleARPA-H's 2026 SBIR/STTR BAA opens seven transformative health topics with $600K Phase I and $3.5M Phase II contracts — non-dilutive, milestone-driven money. The July 10 Solution Summary gate decides who ever gets to pitch. Here's how the ARPA-H model differs from NIH and how small health-tech firms actually get through the funnel.
Read articleARPA-H's FY2026 SBIR/STTR solicitation closes its Solution Summary stage July 10, with seven named topics spanning women's health, autoimmune diagnostics, toxin removal, and neurosurgical robotics. Awards run up to $600K for Phase I and $3.5M for Phase II — but they are contracts, not grants, and the four-to-six-page summary is the gate that filters out most applicants. Here is how ARPA-H's model actually works and how to win the first stage.
Read article